Literature DB >> 21046180

The effect of SNCA 3' region on the levels of SNCA-112 splicing variant.

Jeanette J McCarthy1, Colton Linnertz, Laura Saucier, James R Burke, Christine M Hulette, Kathleen A Welsh-Bohmer, Ornit Chiba-Falek.   

Abstract

Genetic variability at the 3' region of SNCA locus has been repeatedly associated with susceptibility to sporadic Parkinson's disease (PD). Accumulated evidence emphasizes the importance of SNCA dosage and expression levels in PD pathogenesis. However, the mechanism through which the 3' region of SNCA gene modulates the risk to develop sporadic PD remained elusive. We studied the effect of PD risk-associated variants at SNCA 3' regions on SNCA112-mRNA (exon 5 in-frame skipping) levels in vivo in 117 neuropathologically normal, human brain frontal cortex samples. SNPs tagging the SNCA 3' showed significant effects on the relative levels of SNCA112-mRNA from total SNCA transcripts levels. The "risk" alleles were correlated with increased expression ratio of SNCA112-mRNA from total. We provide evidence for functional consequences of PD-associated SNCA gene variants at the 3' region, suggesting that genetic regulation of SNCA splicing plays an important role in the development of the disease. Further studies to determine the definite functional variant/s within SNCA 3'and to establish their association with PD pathology are necessary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21046180      PMCID: PMC3030669          DOI: 10.1007/s10048-010-0263-4

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  30 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

2.  Gene expression profiling in single cells from the pancreatic islets of Langerhans reveals lognormal distribution of mRNA levels.

Authors:  Martin Bengtsson; Anders Ståhlberg; Patrik Rorsman; Mikael Kubista
Journal:  Genome Res       Date:  2005-10       Impact factor: 9.043

3.  Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.

Authors:  Ornit Chiba-Falek; Grisel J Lopez; Robert L Nussbaum
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

4.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

5.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

Authors:  Demetrius M Maraganore; Mariza de Andrade; Alexis Elbaz; Matthew J Farrer; John P Ioannidis; Rejko Krüger; Walter A Rocca; Nicole K Schneider; Timothy G Lesnick; Sarah J Lincoln; Mary M Hulihan; Jan O Aasly; Tetsuo Ashizawa; Marie-Christine Chartier-Harlin; Harvey Checkoway; Carlo Ferrarese; Georgios Hadjigeorgiou; Nobutaka Hattori; Hideshi Kawakami; Jean-Charles Lambert; Timothy Lynch; George D Mellick; Spiridon Papapetropoulos; Abbas Parsian; Aldo Quattrone; Olaf Riess; Eng-King Tan; Christine Van Broeckhoven
Journal:  JAMA       Date:  2006-08-09       Impact factor: 56.272

6.  Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease.

Authors:  Ikuko Mizuta; Wataru Satake; Yuko Nakabayashi; Chiyomi Ito; Satoko Suzuki; Yoshio Momose; Yoshitaka Nagai; Akira Oka; Hidetoshi Inoko; Jiro Fukae; Yuko Saito; Motoji Sawabe; Shigeo Murayama; Mitsutoshi Yamamoto; Nobutaka Hattori; Miho Murata; Tatsushi Toda
Journal:  Hum Mol Genet       Date:  2006-02-24       Impact factor: 6.150

7.  Multiple regions of alpha-synuclein are associated with Parkinson's disease.

Authors:  Jakob C Mueller; Julia Fuchs; Anne Hofer; Alexander Zimprich; Peter Lichtner; Thomas Illig; Daniela Berg; Ullrich Wüllner; Thomas Meitinger; Thomas Gasser
Journal:  Ann Neurol       Date:  2005-04       Impact factor: 10.422

Review 8.  Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers.

Authors:  Katrin Beyer
Journal:  Acta Neuropathol       Date:  2006-07-15       Impact factor: 17.088

9.  Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid.

Authors:  K Uéda; T Saitoh; H Mori
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

10.  The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease.

Authors:  D Campion; C Martin; R Heilig; F Charbonnier; V Moreau; J M Flaman; J L Petit; D Hannequin; A Brice; T Frebourg
Journal:  Genomics       Date:  1995-03-20       Impact factor: 5.736

View more
  30 in total

1.  A search for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease.

Authors:  Lucía F Cardo; Eliecer Coto; Lorena de Mena; René Ribacoba; Oswaldo Lorenzo-Betancor; Pau Pastor; Lluis Samaranch; Ignacio F Mata; Marta Díaz; Germán Moris; Manuel Menéndez; Ana I Corao; Victoria Alvarez
Journal:  J Mol Neurosci       Date:  2011-11-11       Impact factor: 3.444

2.  SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder.

Authors:  M Toffoli; E Dreussi; E Cecchin; M Valente; N Sanvilli; M Montico; S Gagno; M Garziera; M Polano; M Savarese; G Calandra-Buonaura; F Placidi; M Terzaghi; G Toffoli; G L Gigli
Journal:  Neurol Sci       Date:  2017-04-13       Impact factor: 3.307

Review 3.  Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.

Authors:  Subhrangshu Guhathakurta; Eugene Bok; Baggio A Evangelista; Yoon-Seong Kim
Journal:  Prog Neurobiol       Date:  2017-04-23       Impact factor: 11.685

4.  Reduced expression of α-synuclein in alcoholic brain: influence of SNCA-Rep1 genotype.

Authors:  Paulina Janeczek; Rachel K MacKay; Rodney A Lea; Peter R Dodd; Joanne M Lewohl
Journal:  Addict Biol       Date:  2012-09-13       Impact factor: 4.280

5.  Alpha-synuclein (SNCA) polymorphisms exert protective effects on memory after mild traumatic brain injury.

Authors:  Kevin Shee; Alexandra Lucas; Laura A Flashman; Kwangsik Nho; Gregory J Tsongalis; Brenna C McDonald; Andrew J Saykin; Thomas W McAllister; C Harker Rhodes
Journal:  Neurosci Lett       Date:  2016-07-29       Impact factor: 3.046

6.  New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases.

Authors:  Katrin Beyer; Ana M Munoz-Marmol; Carolina Sanz; Ruth Marginet-Flinch; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2011-12-29       Impact factor: 2.660

Review 7.  Genetic variability in SNCA and Parkinson's disease.

Authors:  Lasse Pihlstrøm; Mathias Toft
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

8.  Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.

Authors:  Jesse R McLean; Penelope J Hallett; Oliver Cooper; Michael Stanley; Ole Isacson
Journal:  Mol Cell Neurosci       Date:  2011-12-06       Impact factor: 4.314

9.  A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.

Authors:  Lasse Pihlstrøm; Cornelis Blauwendraat; Chiara Cappelletti; Victoria Berge-Seidl; Margrete Langmyhr; Sandra Pilar Henriksen; Wilma D J van de Berg; J Raphael Gibbs; Mark R Cookson; Andrew B Singleton; Mike A Nalls; Mathias Toft
Journal:  Ann Neurol       Date:  2018-08-26       Impact factor: 10.422

Review 10.  α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.

Authors:  Katrin Beyer; Aurelio Ariza
Journal:  Mol Neurobiol       Date:  2012-08-25       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.